Formic Acid

Formic Acid

SCHEMBL7095402

CCCCCCN(C(N)=O)c1ccc(S(=O)(=O)N2CCC(Nc3ccc(CCN)cc3)CC2)cc1.O=CO

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 2/20 0.41
CCR6 P51684 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA5A P35218 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA13 Q8N1Q1 1/20 0.39
CA14 Q9ULX7 1/20 0.39
TGM2 P21980 1/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
POLB P06746 1/20 0.37
ADRB1 P08588 3/20 0.37
ADRB3 P13945 3/20 0.37
ADRB2 P07550 2/20 0.37
ALDH1A1 P00352 2/20 0.37
NAMPT P43490 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7569465 0.85 CCR6 (0.43) CCR6LMNASMN1; SMN2ADRB1ADRB3
Formic Acid SCHEMBL7091575 0.82 GHSR (0.62) GHSRCA12CA1CA2CA9
SCHEMBL7094231 0.81 SPHK1 (0.41) CA12CA1CA2CA9ADRB3
SCHEMBL7091577 0.80 GHSR (0.45) GHSRCCR6TGM2ADRB1ADRB3
SCHEMBL7571805 0.78 ADRB3 (0.45) ADRB1ADRB3ADRB2
SCHEMBL7091415 0.76 KMT2A (0.59) SMN1; SMN2POLBALDH1A1MEN1KMT2A
SCHEMBL7094586 0.75 CA12 (0.64) CCR6CA12CA1CA2CA4
Formic Acid SCHEMBL7092003 0.73 GNAI3 (0.48) ADRB1ADRB3
SCHEMBL7095496 0.72 EPHX2 (0.47) GHSRCA12CA1CA2CA4
Formic Acid SCHEMBL7095796 0.71 ADRB3 (0.61) GHSRADRB1ADRB3NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6605618-B2 Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction WYETH 2003-08-12 US disclosed
US-20030018045-A1 Heterocyclic beta-3 adrenergic receptor agonists WYETH (US) 2003-01-23 US disclosed
US-6451814-B1 SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION WYETH 2002-09-17 US disclosed
US-20020028832-A1 Heterocyclic beta-3 adrenergic receptor agonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018045-A1 Heterocyclic beta-3 adrenergic receptor agonists ADRB2, ADRB1, ADRB3 GHSR 95/4885CCR6 3035/4885CA12 4814/4885
US-20020028832-A1 Heterocyclic beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 GHSR 88/4885CCR6 3060/4885CA12 4838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.